Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients
- PMID: 20517178
- DOI: 10.1097/MD.0b013e3181d50928
Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients
Abstract
Porphyria cutanea tarda is the most frequent porphyria and occurs in both sporadic and familial forms. We conducted the current study in a series of 152 consecutive patients with porphyria cutanea tarda attending the Porphyria Unit of the Hospital Clinic of Barcelona, Spain, to update the clinical manifestations of the disease and to study the sex differences, the proportion of familial forms, and the role of different risk factors in this population. Patients were classified as familial and sporadic cases according to erythrocyte uroporphyrinogen-decarboxylase activity and uroporphyrinogen-decarboxylase genotyping. In our cohort, skin fragility and blisters on the hands were the most frequent clinical manifestations. Women more frequently had facial hypertrichosis (84.8%; p = 0.004), affected areas other than the hands and face (33.3%; p = 0.008), and pruritus (27.3%; p = 0.041) compared with men. Of our patients, 11.8% did not present the typical clinical onset of the disease, with facial hypertrichosis and hyperpigmentation the more frequent complaints in these cases. Analysis of risk factors showed a high prevalence of hepatitis C virus infection (65.8%) and alcohol abuse (59.9%), both being more frequent in men (p < 0.001). Hepatitis C virus infection was the only risk factor that showed differences between the sporadic and familial forms in the logistic regression model (odds ratio, 0.05; 95% confidence interval, 0.006-0.46). In conclusion, atypical forms of presentation of porphyria cutanea tarda should be considered in order to prevent delayed diagnosis. We note the sustained role of hepatitis C virus infection in the precipitation of sporadic porphyria cutanea tarda. Therefore, in countries with a high prevalence of hepatitis C virus infection, the absence of such infection in a patient with porphyria cutanea tarda may suggest a possible familial case.
Similar articles
-
Familial and sporadic porphyria cutanea tarda: clinical, biochemical and genetic features with emphasis on iron status.Acta Derm Venereol. 2003;83(2):115-20. doi: 10.1080/00015550310007454. Acta Derm Venereol. 2003. PMID: 12735639
-
Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda.J Invest Dermatol. 2000 Nov;115(5):868-74. doi: 10.1046/j.1523-1747.2000.00148.x. J Invest Dermatol. 2000. PMID: 11069625
-
A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: biochemical and genetic studies on Spanish patients.J Invest Dermatol. 1995 Apr;104(4):500-2. doi: 10.1111/1523-1747.ep12605953. J Invest Dermatol. 1995. PMID: 7706766
-
Porphyria cutanea tarda--when skin meets liver.Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):735-45. doi: 10.1016/j.bpg.2010.07.002. Best Pract Res Clin Gastroenterol. 2010. PMID: 20955974 Review.
-
Porphyria cutanea tarda.Semin Liver Dis. 1998;18(1):67-75. doi: 10.1055/s-2007-1007142. Semin Liver Dis. 1998. PMID: 9516680 Review.
Cited by
-
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.Semin Liver Dis. 2024 May;44(2):209-225. doi: 10.1055/s-0044-1787076. Epub 2024 May 17. Semin Liver Dis. 2024. PMID: 38772406 Free PMC article. Review.
-
A case of Myhre syndrome mimicking juvenile scleroderma.Pediatr Rheumatol Online J. 2020 Sep 11;18(1):72. doi: 10.1186/s12969-020-00466-1. Pediatr Rheumatol Online J. 2020. PMID: 32917212 Free PMC article.
-
Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study.Health Qual Life Outcomes. 2020 Mar 30;18(1):84. doi: 10.1186/s12955-020-01328-w. Health Qual Life Outcomes. 2020. PMID: 32228630 Free PMC article.
-
Porphyria Cutanea Tarda Associated With Acute Hemorrhagic Pancreatitis.J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619852769. doi: 10.1177/2324709619852769. J Investig Med High Impact Case Rep. 2019. PMID: 31155958 Free PMC article.
-
Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study.Orphanet J Rare Dis. 2019 Apr 3;14(1):77. doi: 10.1186/s13023-019-1051-3. Orphanet J Rare Dis. 2019. PMID: 30944007 Free PMC article.
References
-
- Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem. 2009;55:795-803.
-
- Badenas C, To-Figueras J, Phillips JD, Warby CA, Munoz C, Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet. 2009;75:346-353.
-
- Bleasel NR, Varigos GA. Porphyria cutanea tarda. Australas J Dermatol. 2000;41:197-206.
-
- Boffa MJ, Reed P, Weinkove C, Ead RD. Hypertrichosis as the presenting feature of porphyria cutanea tarda. Clin Exp Dermatol. 1995;20:62-64.
-
- Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, LeClair P, Mercurio MG, Lambrecht RW. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 1998;27:1661-1669.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
